

RSV Vaccine Services Procedure Code 90382 to Be Updated as Informational Effective July 1, 2025

Last updated on July 10, 2026

Parkland Community Health Plan (PCHP) is sharing an important Texas Medicaid update regarding billing and reimbursement for respiratory syncytial virus (RSV) monoclonal antibody products. Effective for dates of service on or after July 1, 2025, procedure code 90382 (clesrovimab) will process as informational only. Reimbursement may be available for RSV monoclonal antibody administration services when billed with the appropriate administration procedure codes 96380 or 96381.

RSV monoclonal antibody products, including nirsevimab (procedure codes 90380 and 90381) and clesrovimab (procedure code 90382), are available through the Texas Vaccines for Children (TVFC) Program. Texas Medicaid does not reimburse vaccine product claims for members from birth through 18 years of age when administered at a provider site eligible for TVFC enrollment. Claims for these products will be processed in the Medicaid Management Information System (MMIS) as informational records.

Claims Reprocessing

The Texas Medicaid & Healthcare Partnership (TMHP) will reprocess any affected claims with dates of service from July 1, 2025, through August 1, 2026. Providers may receive additional reimbursement, which will be reflected on future Remittance and Status (R&S) Reports.

TMPPM Updates

On August 1, 2026, TMHP will update the *Texas Medicaid Provider Procedures Manual (TMPPM)* to differentiate between RSV vaccine procedure and administration codes and RSV monoclonal antibody procedure and administration codes.

The following updates will be made to the *TMPPM, Children's Services Handbook*, section 4.5.5, "Respiratory Syncytial Virus (RSV)":

- RSV monoclonal antibodies (nirsevimab, procedure codes 90380 and 90381) may be administered to clients from birth through 19 months of age and are limited to two per lifetime.
- RSV monoclonal antibodies (clesrovimab, procedure code 90382) may be administered to clients from birth through 7 months of age and are limited to one per lifetime.
- Procedure codes 96380 and 96381 must be used in conjunction with one of the monoclonal antibodies procedure codes (90380, 90381, or 90382) for reimbursement for monoclonal antibody administration.

The following updates will be made to the *TMPPM, Medical and Nursing Specialists, Physicians, and Physician Assistants Handbook*, section 9.2.39, "Respiratory Syncytial Virus (RSV)":

- RSV vaccine (procedure codes 90679 and 90683) may be reimbursed for clients from 50 years of age or older.
 - RSV monoclonal antibodies (clesrovimab, procedure code 90382) may be administered to clients from birth through 7 months of age and are limited to two per lifetime.
 - RSV monoclonal antibodies (nirsevimab, procedure codes 90380 and 90381) may be administered to clients from birth through 19 months of age and are limited to one per lifetime.
-